{"id":"https://openalex.org/W3213087726","doi":"https://doi.org/10.1182/blood-2021-148891","title":"Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay","display_name":"Prediction of Clinical Response to Venetoclax Plus Decitabine in AML Using a 7-Day Ex Vivo Assay","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3213087726","doi":"https://doi.org/10.1182/blood-2021-148891","mag":"3213087726"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-148891","doi":"https://doi.org/10.1182/blood-2021-148891","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-148891","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019176812","display_name":"Markus Daniel Lacher","orcid":"https://orcid.org/0000-0003-2597-5704","observed_orcids":["https://orcid.org/0000-0003-2597-5704"]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Markus D Lacher","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Michelle A Richardson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle A Richardson","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012758116","display_name":"Steven A. Schaffert","orcid":"https://orcid.org/0000-0001-8842-0218","observed_orcids":["https://orcid.org/0000-0001-8842-0218"]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven A Schaffert","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015965610","display_name":"Ryosuke Kita","orcid":"https://orcid.org/0000-0003-4526-5275","observed_orcids":["https://orcid.org/0000-0003-4526-5275"]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryosuke Kita","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112443184","display_name":"Marianne T. Santaguida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marianne T Santaguida","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043152088","display_name":"Erica K. Anderson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erica K Anderson","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033283917","display_name":"Jordan Roselli","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordan Roselli","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084997012","display_name":"Wade C. Anderson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wade Anderson","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085217253","display_name":"Arisa Paul","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arisa Paul","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031373184","display_name":"Christine J. Gu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Gu","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060461293","display_name":"Kathryn E. Vanderlaag","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210130485","display_name":"Notable Labs (United States)","ror":"https://ror.org/03b9h7664","country_code":"US","type":"company","lineage":["https://openalex.org/I4210130485"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kathryn Vanderlaag","raw_affiliation_strings":["Notable Labs, Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Notable Labs, Foster City, CA","institution_ids":["https://openalex.org/I4210130485"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042269275","display_name":"Zhihong Zeng","orcid":"https://orcid.org/0000-0003-2207-9584","observed_orcids":["https://orcid.org/0000-0003-2207-9584"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhihong Zeng","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075581944","display_name":"Abhishek Maiti","orcid":"https://orcid.org/0000-0001-9043-538X","observed_orcids":["https://orcid.org/0000-0001-9043-538X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abhishek Maiti","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010786159","display_name":"Courtney Denton Dinardo","orcid":"https://orcid.org/0000-0001-9003-0390","observed_orcids":["https://orcid.org/0000-0001-9003-0390"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Courtney D. DiNardo","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022647201","display_name":"Marina Y Konopleva","orcid":"https://orcid.org/0000-0002-9347-2212","observed_orcids":["https://orcid.org/0000-0002-9347-2212"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marina Konopleva","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"3464","last_page":"3464"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.968999981880188},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":1.0},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.7350000143051147},{"id":"https://openalex.org/keywords/nonresponders","display_name":"non-responders","score":0.7200000286102295},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.7620000243186951},{"id":"https://openalex.org/keywords/relapsed-refractory-aml","display_name":"relapsed/refractory AML","score":0.8640000224113464},{"id":"https://openalex.org/keywords/elderly-patients","display_name":"elderly patients","score":0.6179999709129333},{"id":"https://openalex.org/keywords/t-cell-subsets","display_name":"T cell subsets","score":0.6579999923706055},{"id":"https://openalex.org/keywords/cd4-t-cells","display_name":"CD4+ T cells","score":0.4090000092983246},{"id":"https://openalex.org/keywords/cd8-t-cells","display_name":"CD8+ T cells","score":0.8730000257492065},{"id":"https://openalex.org/keywords/natural-killer-cells","display_name":"natural killer cells","score":0.5860000252723694},{"id":"https://openalex.org/keywords/b-cells","display_name":"B cells","score":0.4650000035762787},{"id":"https://openalex.org/keywords/nk-cell-degranulation","display_name":"NK cell degranulation","score":0.5099999904632568}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.8897971510887146},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.8025387525558472},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.5994505286216736},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5421867966651917},{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.49659377336502075},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3798583745956421},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3725877106189728},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.36687567830085754},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3311311602592468},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3304334282875061},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32811999320983887},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.26963406801223755},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.16930148005485535},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.11613661050796509},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-148891","doi":"https://doi.org/10.1182/blood-2021-148891","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-148891","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4405053564","https://openalex.org/W2905241592","https://openalex.org/W4389222046","https://openalex.org/W4389247510","https://openalex.org/W4417005741","https://openalex.org/W3213145896","https://openalex.org/W4403057361","https://openalex.org/W3214538366","https://openalex.org/W4310127695","https://openalex.org/W4311582377"],"abstract_inverted_index":{"Abstract":[0],"INTRODUCTION:":[1],"The":[2,270],"combination":[3,44,327],"of":[4,35,108,115,167,216,223,256,305,336,345,366,374,404,423,434,493,563,575,592,597,626,638,658,679,692,714,735,749,763,777,791,816,828,845,897],"venetoclax":[5],"(VEN)":[6],"and":[7,112,145,189,219,286,300,322,343,356,407,442,538,541],"a":[8,33,73,140,155,159,334,554,589,630,642,662,683,696,718,739,753,767,781,795,820,872,901],"hypomethylating":[9],"agent":[10],"(HMA)":[11],"such":[12,43],"as":[13,133,472],"decitabine":[14],"(DEC)":[15],"is":[16,32,131,273],"frequently":[17],"used":[18],"in":[19,253,292,319,326,426,457,515,533,577,582,629,641,647,661,667,682,695,701,717,723,738,752,766,780,794,802,819,900],"acute":[20],"myeloid":[21],"leukemia":[22],"(AML)":[23],"for":[24,27,93,171,187,248,268,333,463],"patients":[25,36,94,126],"unfit":[26],"standard":[28],"chemotherapy.":[29],"However,":[30],"there":[31],"subset":[34],"who":[37,465],"do":[38],"not":[39],"clinically":[40,77],"respond":[41,78],"to":[42,53,70,79,138,250,358,387,529,545,551,553,566,608],"therapies.":[45],"To":[46,103,418],"identify":[47,546],"VEN":[48,82,210,226,325,370,532,569],"+":[49,81,369,531,568],"HMA":[50],"non-responders":[51,547],"prior":[52],"treatment":[54,141,266,290,373,455,485,505,537,558],"we":[55,439],"developed":[56],"an":[57,84,147,825,842],"assay":[58],"on":[59,184,190,213,220,230,298,445,824,841],"our":[60,109,598],"automated,":[61],"high":[62,160],"throughput":[63],"(HTS)":[64],"ex":[65,371,534],"vivo":[66,340,372,427,535,578],"drug":[67,536],"sensitivity":[68],"platform":[69],"predict":[71,526],"how":[72],"given":[74],"patient":[75,156],"will":[76],"DEC":[80,179,368,530,567],"within":[83,302],"ongoing,":[85],"open":[86],"label,":[87],"phase":[88],"II":[89],"clinical":[90,359,527,564,594],"trial":[91],"(NCT03404193)":[92],"with":[95,158,201,324,328,429,474,509,580],"newly":[96],"diagnosed":[97],"elderly/unfit":[98],"or":[99,198,240,259,431,451,468,480,513,830,847],"relapsed/refractory":[100],"(R/R)":[101],"AML.":[102],"maximize":[104],"the":[105,165,254,265,306,367,421,498,561,610,648,668,702,724,803],"predictive":[106],"power":[107],"assay,":[110],"blast":[111,238,341,377,424,448,475,511,517],"T":[113,346,410,495,584],"cells":[114,316,411,496],"baseline":[116,285,375,396],"samples":[117,397,524],"were":[118,282,296,317,331,349,383,470],"phenotyped,":[119],"using":[120],"multiparameter":[121],"flow":[122,353],"cytometry.":[123],"Identifying":[124],"non-responding":[125],"before":[127,560],"they":[128],"are":[129,606],"treated":[130,323],"important":[132],"it":[134],"would":[135,153,570],"enable":[136],"them":[137,550],"avoid":[139],"failure,":[142],"unnecessary":[143],"toxicity,":[144],"prioritize":[146],"alternative":[148],"treatment.":[149],"Importantly,":[150],"this":[151,172],"approach":[152],"define":[154],"population":[157],"unmet":[161],"medical":[162],"need,":[163],"warranting":[164],"development":[166],"new":[168],"therapeutics":[169],"specifically":[170],"population.":[173],"METHODS:":[174],"In":[175],"NCT03404193,":[176],"participants":[177],"received":[178,209],"IV":[180],"over":[181],"1":[182,218,615],"hour":[183],"Days":[185,191,214,221],"1-10":[186],"induction":[188],"1-5":[192],"after":[193,289,364,454,484,504],"achieving":[194],"complete":[195,199],"remission":[196,200],"(CR)":[197],"incomplete":[202],"count":[203],"recovery":[204],"(CRi)":[205],"during":[206],"consolidation/maintenance.":[207],"Participants":[208],"PO":[211],"daily":[212],"1-28":[215],"Cycle":[217,293,458],"1-21":[222],"subsequent":[224],"cycles.":[225],"could":[227],"be":[228,588],"stopped":[229],"Day":[231],"21":[232],"if":[233],"bone":[234],"marrow":[235],"analysis":[236,355],"showed":[237],"clearance":[239],"hypocellularity.":[241],"Treatment":[242],"cycles":[243,252],"repeated":[244],"every":[245],"4-6":[246],"weeks":[247],"up":[249],"24":[251,650,670,704,726,805],"absence":[255],"disease":[257],"progression":[258],"unacceptable":[260],"toxicity.":[261],"Fig.":[262],"1A":[263],"outlines":[264],"schedule":[267],"NCT03404193.":[269],"primary":[271],"objective":[272],"overall":[274],"response":[275,528,565],"rate":[276],"(ORR).":[277],"Peripheral":[278],"blood":[279,307,311],"(PB)":[280],"specimens":[281],"obtained":[283],"at":[284,497],"3\u00b11":[287],"days":[288,304,363,453,503],"begin":[291,456],"1.":[294,459,617],"Specimens":[295],"shipped":[297],"ice":[299],"processed":[301],"1-4":[303],"draws.":[308],"Following":[309],"red":[310],"cell":[312,347,437,585],"(RBC)":[313],"lysis,":[314],"nucleated":[315],"seeded":[318],"multi-well":[320],"plates":[321],"DEC.":[329],"Cells":[330],"cultured":[332],"total":[335],"7":[337,362],"days.":[338],"Ex":[339],"reduction":[342,425,574],"frequencies":[344],"subtypes":[348],"evaluated":[350],"via":[351],"multiparametric":[352],"cytometry":[354],"compared":[357,386],"response.":[360,595],"RESULTS:":[361],"initiation":[365],"samples,":[376],"counts":[378,449,518],"from":[379,389,398,413],"Responders":[380,488],"(Rs,":[381],"N=2)":[382],"markedly":[384],"reduced":[385],"those":[388],"Non-Responders":[390],"(NRs,":[391],"N=4)":[392],"(Fig.":[393,416,520],"1B).":[394],"Furthermore,":[395],"Rs":[399,441],"(N=9)":[400],"exhibited":[401,490],"higher":[402,491],"levels":[403,433,476,492,586],"both":[405],"CD4+":[406,494],"CD8+":[408],"na\u00efve":[409],"than":[412,507],"NRs":[414,443],"(N=7)":[415],"1C).":[417],"assess":[419],"whether":[420],"kinetics":[422],"correlates":[428],"increased":[430],"decreased":[432],"certain":[435],"immune":[436],"subsets":[438],"re-defined":[440],"based":[444],"their":[446,516],"baseline-normalized":[447],"2":[450,478],"4":[452,482],"Rapid":[460,487,573],"Responders,":[461],"enriched":[462],"subjects":[464,473,508],"experienced":[466],"CRs":[467],"CRi's,":[469],"defined":[471],"\u226450%":[477],"days,":[479,483],"\u226433%":[481],"begin.":[486],"(N=6)":[489],"evaluation":[499],"time":[500],"point":[501],"(2-4":[502],"begin)":[506],"slower":[510],"reductions":[512],"increases":[514,581],"(N=4)":[519],"1D).":[521],"CONCLUSIONS:":[522],"Baseline":[523],"may":[525,542,587],"immunophenotyping":[539],"assays":[540],"consequently":[543],"serve":[544],"early,":[548],"allowing":[549],"switch":[552],"potentially":[555],"more":[556],"effective":[557],"regimen":[559],"lack":[562],"become":[571],"apparent.":[572],"blasts":[576],"coupled":[579],"CD4":[583],"prognostic":[590],"indicator":[591],"good":[593],"Limitations":[596],"laboratory":[599],"study":[600],"include":[601],"small":[602],"sample":[603],"sizes.":[604],"Efforts":[605],"underway":[607],"validate":[609],"trends":[611],"reported":[612],"here.":[613],"Figure":[614,616],"Disclosures":[618],"Lacher:":[619],"Notable":[620,634,653,673,687,710,729,743,757,771,785,812],"Labs:":[621,635,654,674,688,711,730,744,758,772,786,813],"Current":[622,624,636,656,675,677,690,712,731,733,745,747,759,761,773,775,787,789,814,895],"Employment,":[623,676,732,746,760,774,788],"holder":[625,637,657,678,691,713,734,748,762,776,790,815,896],"stock":[627,639,659,680,736,750,764,778,792,817,898],"options":[628,640,660,681,737,751,765,779,793,818,899],"privately-held":[631,643,663,684,697,719,740,754,768,782,796,821,902],"company.":[632,685,741,755,769,783],"Richardson:":[633],"company,":[644,664,698,720,822,903],"Ended":[645,665,699,721,800],"employment":[646,666,700,722,801],"past":[649,669,703,725,804],"months.":[651,671,727,806],"Schaffert:":[652],"Consultancy,":[655,689,853,866,954,960,974],"Kita:":[672],"Santaguida:":[686],"individual":[693,715],"stocks":[694,716],"months,":[705],"Patents":[706,904,926,937],"&":[707,905,927,938],"Royalties.":[708],"Anderson:":[709,742],"Roselli:":[728],"Paul:":[756],"Gu:":[770],"Vanderlaag:":[784],"company;":[797],"Bristol-Myers":[798],"Squibb:":[799,835],"DiNardo:":[807],"ImmuneOnc:":[808],"Honoraria,":[809,836,854,858,862,877,955,961,975],"Research":[810,837,855,859,863,867,878,885,891,912,919,933,943,949,965,971,979,985,991,1002],"Funding;":[811,838,856,860,864,868,886,892,913,920,934,944,950,966,972,980,986,992],"Membership":[823,840],"entity's":[826,843],"Board":[827,844],"Directors":[829,846],"advisory":[831,848],"committees;":[832,849],"Bristol":[833,873],"Myers":[834,874],"GlaxoSmithKline:":[839],"Takeda:":[850],"Honoraria;":[851,870],"Agios/Servier:":[852],"Forma:":[857],"Foghorn:":[861],"AbbVie:":[865,973],"Novartis:":[869,921],"Celgene,":[871],"Squibb":[875],"company:":[876],"Funding.":[879,1003],"Konopleva:":[880],"Agios:":[881],"Other:":[882,888,916,922,946,956,962,968,976,982,988,994,999],"grant":[883,889,917,947,957,963,969,983,989,995,1000],"support,":[884,890,918,948,964,970,984,990,1001],"Ablynx:":[887],"Reata":[893],"Pharmaceuticals:":[894,915],"Royalties:":[906,928,939],"intellectual":[907,929,940],"property":[908,930,941],"rights;":[909,931],"Stemline":[910],"Therapeutics:":[911],"Rafael":[914],"research":[923],"funding":[924],"pending,":[925],"KisoJi:":[932],"Eli":[935],"Lilly:":[936],"rights,":[942],"Ascentage:":[945],"F.":[951],"Hoffmann-La":[952],"Roche:":[953],"support;":[958,996],"Genentech:":[959],"AstraZeneca:":[967],"Grant":[977],"Support,":[978],"Sanofi:":[981],"Calithera:":[987],"Cellectis:":[993],"Forty":[997],"Seven:":[998]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-11-22T00:00:00"}